Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.60 |
| ▸ | GSK3A | P49840 | 5/20 | 0.54 |
| ▸ | AURKA | O14965 | 12/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578612 | 0.89 | GSK3B (0.53) | GSK3BCHEK1NTRK2GSK3AAURKA | |
| SCHEMBL2523254 | 0.83 | GSK3B (0.54) | GSK3BCHEK1NTRK2GSK3AAURKA | |
| SCHEMBL14621366 | 0.83 | AURKA (0.59) | GSK3BCHEK1NTRK2GSK3AAURKA | |
| SCHEMBL3125757 | 0.82 | IGF1R (0.68) | GSK3BNTRK2GSK3AAURKAAURKB | |
| SCHEMBL5262378 | 0.81 | GSK3B (1.00) | GSK3BCHEK1NTRK2GSK3AAURKA | |
| SCHEMBL579089 | 0.80 | GSK3B (0.70) | GSK3BGSK3AAURKAAURKBJAK2 | |
| SCHEMBL13808057 | 0.79 | CDK2 (0.49) | GSK3BAURKANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5262926 | 0.79 | GSK3B (0.81) | GSK3BCHEK1NTRK2GSK3AAURKA | |
| SCHEMBL3645658 | 0.79 | GSK3B (0.61) | GSK3BCHEK1NTRK2GSK3AAURKA | |
| SCHEMBL12212276 | 0.78 | IGF1R (0.59) | AURKAAURKBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2027107-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| CN-101213179-A | 2, 4-diamino-pyrimidines as Aurora inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2008-07-02 | — | — | CN | disclosed |
| EP-1902037-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007132010-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132010-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | GSK3B 242/4885CHEK1 66/4885NTRK2 3115/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | GSK3B 242/4885CHEK1 66/4885NTRK2 3115/4885 |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | GSK3B 242/4885CHEK1 66/4885NTRK2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.